BLAINJECTIONINJECTABLE
Approved
May 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
5/8 — Partial
BKEMV (eculizumab-aeeb) by Amgen is complement inhibitors [moa]. Approved for complement inhibitor [epc]. First approved in 2024.
Drug data last refreshed 3h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BKEMV (eculizumab-aeeb) is a monoclonal antibody complement inhibitor approved in May 2024 as a biosimilar referencing the original eculizumab. It works by blocking C5 complement protein to reduce inflammation and cell destruction across multiple rare diseases. The drug is administered by injection and represents Amgen's entry into the competitive complement inhibition space.
Growth
Recently approved biosimilar in growth phase with moderate competitive pressure (30%); commercial team is scaling market access and payer relationships in a specialty setting.
Mechanism of Action
Complement Inhibitors
Pharmacologic Class:
Complement Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on BKEMV at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.